Immune deregulation in myelodysplastic syndromes - the role of cytokines and soluble adhesion molecules. A pilot study
Abstract
A significant effort has been made to innovative treatment approaches in majority of haematooncologic diseases including myelodysplastic syndromes. Adopting novel therapies brings new questions about enhancing their efficacy.
Increasing evidence show a significant role of tumour microenvironment, which compounds of cytokines, chemokines, soluble adhesion molecules, specific T-lymphocyte populations and further populations of antigen presenting cells.In this article, we publish results of our pivotal trial analysing serum levels of cytokines, chemokines and soluble adhesion molecules in patients with high-risk myelodysplastic syndromes treated with hypomethylating agent Azacytidine. We analyse factors associated with levels of measured analytes, overall survival and treatment failure.
Incorporating both clinical and experimental data into analyses helps to achieve a deeper insight into biology of myelodysplastic syndromes and the crosstalk of tumour microenvironment and outcome of therapies in general.